Full-Service CRO Support for CAR T-Cell Therapy Clinical Trials

Launching a CAR T-cell therapy clinical trial requires deep therapeutic expertise, cell therapy know-how, and agile project management. In this real-world case study, a U.S.-based sponsor partnered with TFS to support an adaptive Phase Ib/IIa oncology study targeting lymphoma patients undergoing CAR T-cell treatment.

The study aimed to evaluate a novel compound intended to prevent and treat severe immunotherapy-related complications. Faced with site engagement hurdles, standard-of-care drug supply risks, and an underprepared clinical team, the sponsor turned to TFS for strategic CRO partnership and hands-on trial support.

Download the Case Study to Learn:

• How to optimize site identification and engagement in early-phase oncology trials
  Learn how TFS leveraged its Phase I site network to accelerate start-up and enrollment.
• Best practices for supporting CAR T-cell therapy trial operations
  See how TFS helped navigate complex trial procedures with specialized training and experienced personnel.
• How flexibility and CRO collaboration drive study success
  Discover how TFS’s adaptive contracting, contingency planning, and executive oversight enabled operational agility.
• What matters most in high-stakes hematologic malignancy studies
  Explore how proactive project management and creative solutions can overcome drug supply shortages and team preparedness gaps.

If you’re managing a CAR T-cell therapy clinical trial or planning a study in hematologic malignancies, this case study offers a proven model for overcoming early-stage challenges and delivering executional excellence through a collaborative CRO partnership.

Learn more about our related services and resources:

TFS Oncology & Hematology